Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV

Author:

MacDonald David M.,Samorodnitsky Sarah,Wendt Chris H.,Baker Jason V.,Collins Gary,Kruk Monica,Lock Eric F.,Paredes Roger,Poongulali Selvamuthu,Weise Danielle O.,Winston Alan,Wood Robin,Kunisaki Ken M.,Aagaard B.,Jansson P. O.,Pearson M. T.,Babiker A. G.,Arenas-Pinto A.,Atako N. B.,Dennis E.,Forcat S.,Hudson F.,Jackson B.,Maas D.,Purvis C.,Russell C.,Emery S.,Carey C.,Clewett M.,Jacoby S.,Gordin F.,Vjecha M.,Sanchez A.,Loria G. R.,Doldan M. L.,Moricz A.,Tillmann K.,Müller V.,Touloumi G.,Gioukari V.,Anagnostou O.,Herrero P.,Lopez P.,Avihingsanon A.,Rerksirikul P.,Loiza E.,Mingrone V.,Lupo S.,Marconi F.,Daniel D.,Crinejo A.,French M.,Barba L.,Rowling D.,Warzywoda E.,Bloch M.,Agrawal S.,Dwyer D.,Taylor J.,van Petersen L.,Mertens L.,De Wit S.,Kabamba K.,Wolff M.,Allendes G.,Ristola M.,Debham O.,Jessen H.,Jessen A.,Wiebecke S.,Klinker H.,Fätkenheuer G.,Lehmann C.,Knaevelsrud I.,Rittweger M.,Stöhr A.,Olah K.,Schaaf B.,Hower M.,Harrer T.,Harrer E.,Skoutelis A.,Papastamopoulos V.,Metallidis S.,Tsachouridou O.,Pujari S.,Chitalikar A.,Kumarasamy N.,Beulah F.,Shahar E.,Kedem E.,Turner D.,Madero J. Sierra,Madrigal C.,Filali K. M. El,Erradey I.,Ekong E.,Eriobu N.,Valencia J.,León M.,Montalbán E.,Alave J.,Salazar R.,Vega J.,del Portal M.,Mendo F.,Bakowska E.,Ignatowska A.,Czarnecki M.,Szymczak A.,Wood R.,Rattley M.,Pillay S.,Mngqibisa R.,Ndaba T.,Madlala P.,Estrada V.,Rodrigo M.,Gutierrez M.,Muñoz J.,Dalmau D.,Badia C.,Clotet B.,Llibre J. M.,Ruxrungtham K.,Gatechompol S.,Kiertiburanakul S.,Sanmeema N.,Bowonwatanuwong C.,Ampunpong U.,Prasithsirikul W.,Thongyen S.,Chetchotisakd P.,Anunnatsiri S.,Ratanasuwan W.,Werarak P.,Kityo C.,Mugerwa H.,Munderi P.,Lutaakome J.,Clarke A.,Bexley A.,Das S.,Sahota A.,Emerson C.,McKernan S.,Johnson M. A.,Youle M.,Ross J.,Harding J.,Kegg S.,Moussaoui T.,Chen F.,Lynch S.,de Burgh-Thomas A.,Karunaratne I.,Dockrell D.,Bowman C.,Winston A.,Mora-Peris B.,Chadwick D. R.,Lambert P.,Desai N.,Carter W.,Henry K.,Givot R.,Chow M.,Holloway B.,Weis S.,Vecino I.,Novak R.,Culbert G.,Wilkin A.,Mosley L.,Thielman N.,Granholm J.,Watson V.,Clark C.,Santana J.,Boneta I.,Brar I.,Makohon L.,MacArthur R.,Farrough M.,Frank M.,Parker S.,Tedaldi E.,Santiago M.,Koletar S.,Harber H.,Thomas D.,Bica I.,Adams B.,Van Dam C.,Kolber M.,Moreno K.,Brown A.,Wade B., , , ,

Abstract

AbstractChronic obstructive pulmonary disease (COPD) is among the leading causes of death worldwide and HIV is an independent risk factor for the development of COPD. However, the etiology of this increased risk and means to identify persons with HIV (PWH) at highest risk for COPD have remained elusive. Biomarkers may reveal etiologic pathways and allow better COPD risk stratification. We performed a matched case:control study of PWH in the Strategic Timing of Antiretoviral Treatment (START) pulmonary substudy. Cases had rapid lung function decline (> 40 mL/year FEV1 decline) and controls had stable lung function (+ 20 to − 20 mL/year). The analysis was performed in two distinct groups: (1) those who were virally suppressed for at least 6 months and (2) those with untreated HIV (from the START deferred treatment arm). We used linear mixed effects models to test the relationship between case:control status and blood concentrations of pneumoproteins (surfactant protein-D and club cell secretory protein), and biomarkers of inflammation (IL-6 and hsCRP) and coagulation (d-dimer and fibrinogen); concentrations were measured within ± 6 months of first included spirometry. We included an interaction with treatment group (untreated HIV vs viral suppression) to test if associations varied by treatment group. This analysis included 77 matched case:control pairs in the virally suppressed batch, and 42 matched case:control pairs in the untreated HIV batch (n = 238 total) who were followed for a median of 3 years. Median (IQR) CD4 + count was lowest in the controls with untreated HIV at 674 (580, 838). We found no significant associations between case:control status and pneumoprotein or biomarker concentrations in either virally suppressed or untreated PWH. In this cohort of relatively young, recently diagnosed PWH, concentrations of pneumoproteins and biomarkers of inflammation and coagulation were not associated with subsequent rapid lung function decline.Trial registration: NCT00867048 and NCT01797367.

Funder

National Heart, Lung, and Blood Institute,United States

National Heart, Lung, and Blood Institute

National Institute of Allergy and Infectious Diseases,United States

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3